옵션 체인은 다양한 행사가격과 만기일에 대한 Tevogen Bio Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Tevogen Bio Holdings에 대한 시장 심리를 평가합니다..

Tevogen Bio Holdings (NASDAQ:TVGN) 주식, 옵션 체인

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Tevogen Bio Holdings Inc

WIIM

VRME

VerifyMe shares are trading lower after the company reported worse-than-expected Q4 earnings and sales.

News

Contracts

MRAM

Everspin Awarded $10.5M Contract For MRAM IP And Foundry Services For Purdue University's ME Commons In-Memory Compute Project

<p>Baird  analyst Shrenik Kothari   maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $240 to $250.</p>


Price Target

Analyst Ratings

Baird Maintains Outperform on Zscaler, Raises Price Target to $250

Earnings

Earnings Beats

Earnings Misses

VYNE

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

<p>Baird  analyst Joe Vruwink   maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $283 to $285.</p>


VEEV

Baird Maintains Outperform on Veeva Systems, Raises Price Target to $285

ALLR

Allarity Therapeutics Announces ITs Phase 2 Trial Of Stenoparib In Combination With Temozolomide For Recurrent Small Cell Lung Cancer, Being Fully Funded By US Veterans Administration

<p>Baird  analyst William Power   maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and lowers the price target from $390 to $300.</p>


Baird Maintains Outperform on MongoDB, Lowers Price Target to $300

Curtiss-Wright Receives $18M Follow-On Order From US Marine Corps

<p>No gainer in today's Pre-market session. </p>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">217.58</td>
<td align="right">-3.99</td>
<td align="right">-1.81</td>
<td>19.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.70</td>
<td align="right">-0.51</td>
<td align="right">-1.02</td>
<td>255.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">209.31</td>
<td align="right">-2.10</td>
<td align="right">-1.00</td>
<td>364</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.95</td>
<td align="right">-0.54</td>
<td align="right">-0.70</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">148.93</td>
<td align="right">-0.75</td>
<td align="right">-0.51</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.20</td>
<td align="right">-0.22</td>
<td align="right">-0.51</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.06</td>
<td align="right">-0.38</td>
<td align="right">-0.47</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.34</td>
<td align="right">-0.36</td>
<td align="right">-0.43</td>
<td>13.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.84</td>
<td align="right">-0.20</td>
<td align="right">-0.23</td>
<td>326</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 6, 2025

Tesla shares are trading lower after Baird lowered its price target on the stock from $440 to $370.

<p>Baird  analyst Craig Kennison   maintains Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) with a Outperform and lowers the price target from $110 to $100.</p>


Baird Maintains Outperform on Thor Industries, Lowers Price Target to $100

BECN

Beacon Acquires DM Figley, Terms Not Disclosed

CNTM

ConnectM Secured Over 5,500 Orders For MELI Mobility Edge And AURAI Platform Subscriptions From Existing OEM Customers In First Two Months Of 2025

<p>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.27) by 37.8 percent. This is a 1.25 percent increase over losses of $(0.80) per share from the same period last year.  The company reported quarterly sales of $29.66 million which beat the analyst consensus estimate of $24.91 million by 19.09 percent.  This is a 4.25K percent increase over sales of $682.00 thousand the same period last year.</p>


PHAT

Phathom Pharmaceuticals Q4 Adj $(0.79) Beats $(1.27) Estimate, Sales $29.66M Beat $24.91M Estimate

<p>Baird  analyst Jonathan Komp   maintains Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Neutral and lowers the price target from $24 to $20.</p>


Baird Maintains Neutral on Foot Locker, Lowers Price Target to $20

<p>Baird  analyst Ben Kallo   maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $440 to $370.</p>


Baird Maintains Outperform on Tesla, Lowers Price Target to $370

LFMD

LifeMD Announces Integration With LillyDirect Pharmacy Provider Gifthealth To Offer Access To Branded Dual GLP-1/GIP Zepbound

<p>Needham  analyst Charles Shi   reiterates Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $19 price target.</p>


Reiteration

SVCO

Needham Reiterates Buy on Silvaco Group, Maintains $19 Price Target

<p>Needham  analyst John Todaro   maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and lowers the price target from $16 to $15.</p>


CMPO

Needham Maintains Buy on CompoSecure, Lowers Price Target to $15

<ul>
<li>Adjusted EBITDA of $210 million to $220 million (vs. previous outlook of $200 million to $215 million)</li>
</ul>


Guidance

CBRL

Cracker Barrel Revises FY25 Total Revenue Outlook From $3.4B - $3.5B To $3.45B - $3.50B, Est $3.46B

Financing

Press Releases

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

General

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Health Care

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Management

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

TVGNW

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌